AstraZeneca Staking Its Growth On Oncology; Now It Needs Cancer Drugs
Executive Summary
AstraZeneca has an ambitious agenda to become a leader in oncology. The company’s notably improved pipeline is broad, but winning will require AstraZeneca to come from behind to uncover the best combinations ahead of the competition.
You may also be interested in...
AstraZeneca Scores Lung Cancer Touchdown, While Clovis Fumbles
Both AstraZeneca’s Tagrisso and Clovis’ rociletinib target metastatic EGFR T790M mutation-positive non-small cell lung cancer. Tagrisso was approved by FDA Nov. 13, while Clovis said its drug would be delayed because mature data showed fewer confirmed responses than earlier data.
AstraZeneca Sees Strength In Small Molecules, Starts Building Oncology Franchises
With its first oncology approval in 15 years, an imminent submission for its next cancer drug and a slew of trials starting by the end of the year, AstraZeneca is starting to show how oncology will be a growth platform.
With Oncology Drugs On The Way, AstraZeneca Sets The Stage For New Launches
U.S. President Paul Hudson says AstraZeneca is building specialty commercial team ahead of new oncology launches; MedImmune seals new deals in its quest for winning combinations in immuno-oncology.